Sugi Predict

Sugi Predict / Compounds / SCHEMBL29673201

SCHEMBL29673201

SCHEMBL29673201

O=C1CCCc2c1ccc(F)c2F

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 4/20 0.39
▸ MAOB P27338 4/20 0.39
▸ CYP2A6 P11509 1/20 0.39
▸ PRKCI P41743 1/20 0.39
▸ NOTUM Q6P988 1/20 0.39
▸ PARP1 P09874 1/20 0.37
▸ P2RX7 Q99572 1/20 0.35
▸ HSD17B1 P14061 2/20 0.35
▸ MAPK14 Q16539 2/20 0.34
▸ BRD4 O60885 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ GRM5 P41594 1/20 0.33
▸ CES1 P23141 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4637516 1.00 MAOA (0.39) MAOAMAOBCYP2A6PRKCINOTUM
SCHEMBL30666511 0.88 NOTUM (0.44) NOTUMHSD17B1MAPK14HSD17B10KDM4E
SCHEMBL1339423 0.88 NOTUM (0.44) NOTUMHSD17B1MAPK14HSD17B10KDM4E
SCHEMBL14053140 0.82 MAOA (0.38) MAOAMAOBCYP2A6PRKCIHSD17B1
SCHEMBL22253606 0.81 MAOA (0.41) MAOAMAOBCYP2A6PRKCIPARP1
SCHEMBL4637638 0.81 MAOA (0.37) MAOAMAOBCYP2A6PRKCIPARP1
SCHEMBL6121207 0.81 KDM4E (0.41) MAOAMAOBCYP2A6PRKCIPARP1
SCHEMBL24542979 0.81 NOTUM (0.41) MAOAMAOBCYP2A6PRKCINOTUM
SCHEMBL30070449 0.81 MAOA (0.37) MAOAMAOBCYP2A6PRKCIPARP1
SCHEMBL29673139 0.81 NOTUM (0.41) MAOAMAOBCYP2A6PRKCINOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12398154-B2 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. (US) 2025-08-26 — — US disclosed
WO-2025040767-A1 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER SANOFI (FR) 2025-02-27 — — WO disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 — — EP disclosed
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors Mirati Therapeutics, Inc. 2023-03-09 — — US disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 — — WO disclosed
WO-2022127827-A1 KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 上海维申医药有限公司 2022-06-23 — — WO disclosed
CN-114644631-A KRAS G12C protein mutation inhibitor, preparation method thereof, pharmaceutical composition and application thereof 上海维申医药有限公司 2022-06-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230072276-A1 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS MAOA 4862/4885MAOB 4810/4885CYP2A6 4112/4885
US-12398154-B2 Azaquinazoline pan-KRas inhibitors KRAS, NRAS, HRAS MAOA 4862/4885MAOB 4810/4885CYP2A6 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.